Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab and trastuzumab in metastatic HER2-positive breast cancer (MIMOSA)
2020-000849-14Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of monalizumab and trastuzumab in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Objective response rate. Started Jun 2020; status: completed.
02
Drugs
monalizumabtrastuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2020-000849-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000849-14.